PATH
UiPath, Inc.Thesis. UiPath sits mid-range in its 52-week band at $11.65, backed by $1.22B net cash and 30%+ FCF margins, but revenue growth has cooled to 17% and the agentic-AI narrative remains unproven on ARR. We wait for evidence that Maestro monetization inflects before paying up; balance-sheet resilience limits downside but the setup is range-bound.
Scoreboard
At $11.65, PATH trades 41% below its 52-week high of $19.84 and 27% above the $9.20 low, sitting in the lower quartile (23rd percentile) of its annual range. Market cap of $6.0B against enterprise value of $4.8B reflects the ~$1.2B net-cash cushion. Mean analyst target of $13.25 implies ~14% upside, but the 'hold' consensus (2.8 rating mean) signals muted conviction.
QoQ Changes
FQ (Apr-30) revenue of $418.4M fell 13% QoQ from $481.1M in the seasonally strong Jan quarter, while basic EPS compressed to $0.04 from $0.19. The sequential drop is partly seasonal but underscores a decelerating top-line trajectory versus 17.3% trailing revenue growth.
Gross margin remains best-in-class at 83.1%, but operating margin slid to 6.7% ($28.0M operating income) from ~17% in the prior quarter, and EBITDA margin sits at just 7.4%. The GAAP profitability gap versus gross margin reflects heavy S&M and R&D reinvestment.
FCF margin is exceptional at ~30.6%, translating to an 8.5% FCF yield — a standout for a software name at this multiple. Cash generation, not GAAP earnings, is the core value anchor here.
The company holds $1.31B cash against just $83M debt, for $1.22B net cash ($2.52/share). Current ratio of 2.31 and quick ratio of 2.07 leave zero solvency concern; the reported 4.36 debt/equity is a book-equity artifact, not a leverage flag.
Forward P/E of 12.8x and PEG of 0.43 screen cheap, while EV/revenue of 2.9x is modest for 83% gross margins; EV/EBITDA of 38.9x looks elevated but is distorted by thin GAAP EBITDA. On P/S of 3.6x the stock is de-rated well below its post-IPO peaks.
UiPath launched Maestro Case, an AI-native case-management layer within its orchestration platform, extending beyond legacy RPA into agentic workflows. Headcount stands at 3,981 with revenue/employee of ~$420K; no M&A or restructuring disclosed in the data.
Ownership & Insider Activity
SEC Form 4 data shows April 1 activity dominated by equity awards (code A) to executives — Gupta (COO, +306,748), Brubaker (GC, +157,208), Malpani (CTO, +159,125) — with offsetting tax-withholding sales (code F) at $11.10 totaling ~$5.0M net sells; no open-market purchases (P). Founder Daniel Dines executed offsetting code-J transfers (net zero) around a 27.9M-share balance in March, likely estate/trust reorganization rather than a directional signal. The standout risk is the 31.4% short-of-float (126M shares, 2.64 days to cover) — a heavily contested name where any ARR beat could squeeze.
Recent Insider Transactions
| Date | Insider | Position | Shares | Value |
|---|---|---|---|---|
| 2026-06-25 | SPRINGER DANIEL D | Director | 19,175 | $0.00 |
| 2026-06-25 | TERRELL KARENANN K | Director | 19,175 | $0.00 |
| 2026-06-25 | WONG RICHARD P. | Director | 19,175 | $0.00 |
| 2026-06-25 | GORDON MICHAEL LAWRENCE | Director | 19,175 | $0.00 |
| 2026-06-25 | BOTTERI PHILIPPE | Director | 19,175 | $0.00 |
| 2026-06-25 | YANG JUNE | Director | 19,175 | $0.00 |
Earnings Quality
| Period | Actual EPS | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
| 2026-06-30 Q1 | $0.15 | $0.16 | $-0.01 | -7.86% |
| 2026-03-31 Q4 | $0.30 | $0.26 | +$0.04 | +15.52% |
| 2025-12-31 Q3 | $0.16 | $0.15 | +$0.01 | +7.38% |
| 2025-09-30 Q2 | $0.15 | $0.08 | +$0.07 | +83.60% |
PATH beat consensus in 3 of the last 4 quarters with an outsized average surprise of +24.7%, headlined by an +83.6% beat in Q2 FY26 — signaling conservative guidance calibration by management.
The most recent print (Jun-30) missed by 7.9% ($0.15 vs $0.163 est), breaking the beat streak and suggesting the low-bar guidance dynamic may be normalizing as analysts recalibrate upward.
Analyst Action
| Month | Distribution | Strong Buy | Buy | Hold | Sell | Strong Sell |
|---|---|---|---|---|---|---|
| 2026-07 | 2 | 7 | 18 | 1 | 0 | |
| 2026-06 | 2 | 7 | 18 | 1 | 0 | |
| 2026-05 | 2 | 8 | 17 | 1 | 0 | |
| 2026-04 | 2 | 8 | 17 | 1 | 0 |
The rating panel has drifted marginally more cautious: Buy tallies eased from 8 (Apr-May) to 7 (Jun-Jul) while Hold rose to 18 and one Sell persists; Strong Buy holds steady at 2. UBS cut its target to $12 on June 29 while maintaining Neutral.
Momentum is mildly bearish, with a bullish-drift score of -1 and no upgrades in the trailing 15 days.
Seven Essential Metrics
83.1% gross margin and 18.2% ROE are strong, but 6.7% operating margin and 7.4% EBITDA margin reveal thin GAAP operating leverage.
Revenue growth of 17.3% is solid but decelerating; earnings growth n/a and sequential revenue fell 13% QoQ.
FCF margin of ~30.6% and 8.5% FCF yield anchor the valuation floor.
$1.22B net cash, only $83M total debt; the 4.36 debt/equity is a book-value artifact.
Beta of 0.97 is market-like, but 31.4% short interest and an unproven agentic-AI transition elevate event risk.
Forward P/E 12.8x and PEG 0.43 look cheap, offset by 38.9x EV/EBITDA on thin GAAP EBITDA and 3.6x P/S.
Implied shares outstanding of 518M vs 453M basic point to ongoing SBC dilution; no offsetting buyback evident in data.
No dividend; capital allocation prioritizes reinvestment and platform expansion.
Competitive Snapshot
| Company | EBITDA Margin | 3Y Rev CAGR | FCF Margin | Leverage | Fwd P/E |
|---|---|---|---|---|---|
NOW ServiceNow | ~30% | ~24% | ~30% | Net cash | ~55x |
PEGA Pegasystems | ~20% | ~8% | ~25% | <1x | ~25x |
APPN Appian | ~5% | ~15% | ~5% | Moderate | n/a |
MSFT Microsoft (Power Automate) | ~52% | ~15% | ~28% | Net cash | ~32x |
PATH's 83% gross margin and 30% FCF margin rival ServiceNow, yet it trades at a fraction of NOW's ~55x forward P/E versus its own 12.8x — a valuation discount reflecting slower growth and RPA-commoditization fears. The existential threat is Microsoft bundling Power Automate and Copilot agents, which pressures UiPath's standalone value proposition even as its orchestration depth (Maestro) offers differentiation.
Business & Strategy
Revenue is overwhelmingly subscription/ARR from the UiPath automation platform, spanning RPA, API automation, intelligent document processing, test cloud, and the newer Maestro orchestration and agentic-AI solutions. The strategic shift is from task-level RPA toward enterprise-wide process orchestration coordinating AI agents, robots, and humans.
Serves financial services, healthcare, manufacturing, retail, and public-sector enterprises across the US, Romania, UK, Netherlands, and internationally.
Primarily recurring license and cloud subscriptions with expansion driven by seat/robot growth and net revenue retention; new agentic modules represent an upsell vector.
Sales & marketing and R&D dominate opex, driving the wide gap between 83% gross margin and 7% operating margin.
UiPath's moat rests on switching costs from embedded automations, a large deployed robot base, and centralized governance across agents and tasks. That moat is narrowing as generative-AI agents and hyperscaler bundles threaten to disintermediate legacy screen-scraping RPA.
Monetary-Policy Sensitivity
- Long-duration software multiple expansion
- Improved enterprise IT budget appetite
- Short-covering amplification on risk-on rotation
As an unprofitable-on-GAAP, high-growth-adjacent software name, PATH benefits disproportionately from falling discount rates via multiple re-rating. A dovish pivot would also loosen enterprise automation budgets and could trigger squeezes given the 31% short base.
SWOT Analysis
- 83.1% gross margin, best-in-class for software
- $1.22B net cash, fortress balance sheet
- ~30.6% FCF margin / 8.5% FCF yield
- 82% institutional ownership signals depth
- Revenue growth decelerating to 17%, -13% QoQ
- Thin 6.7% GAAP operating margin
- Persistent SBC dilution (518M vs 453M shares)
- Recent EPS miss broke beat streak
- Maestro agentic-AI orchestration upsell
- Enterprise standardization on unified automation governance
- Multiple re-rating from depressed 12.8x forward P/E
- Short squeeze potential on ARR beat
- Microsoft Power Automate / Copilot bundling
- RPA commoditization by generative AI
- 31.4% short interest reflects entrenched bear thesis
- Slowing enterprise automation budgets
Catalysts & Event Risks
- Q3 2026FQ2 FY27 Earnings
Next print will test whether Maestro and agentic-AI adoption lift ARR, net retention, and margins.
- 2026-Q3Maestro Case Adoption Metrics
Early customer traction data on the AI-native case-management launch could reprice the growth narrative.
- 2026-Q4FY27 ARR guidance update
Management commentary on agentic-AI monetization pace is the key swing factor for the multiple.
- 2026-09Fed rate decision
A dovish shift would support long-duration software multiples and could trigger short-covering.
The binary catalyst is the next earnings readout: proof of ARR acceleration from agentic tools could squeeze the 31% short base, while continued deceleration validates the bear case. Until then, the setup is range-bound.
Technical Analysis
PATH trades at $11.65, above its 50-day ($10.81) but below its 200-day ($12.97) moving average — a stock attempting to base after a 41% decline from highs. Volume of 73M against a 41M average signals elevated interest, likely tied to the Maestro narrative and short positioning. The 52-week low of $9.20 forms firm support with the 200-day at $12.97 as overhead resistance; the risk-reward is balanced within a $9-13 range pending an earnings catalyst.
Verdict
Macro context. Enterprise software spending remains selective as CIOs prioritize demonstrable AI ROI over broad automation buildouts, pressuring RPA-legacy names; a dovish Fed pivot would relieve multiple compression on long-duration growth software.
UiPath is a fortress-balance-sheet, high-FCF automation platform trading at an undemanding 12.8x forward P/E and 0.43 PEG, with genuine optionality in its agentic-AI Maestro pivot. But decelerating 17% revenue growth, a broken EPS-beat streak, ongoing dilution, and a formidable 31% short base keep this a show-me story. We rate HOLD with a $13 target — accumulate below $10 into the earnings catalyst, but demand ARR-acceleration evidence before underwriting the AI re-rate.
Data source: Yahoo Finance / yfinance · fetched 7/8/2026, 6:07:08 AM